Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 105.07 Billion KRW | 14.41% |
| 2022 | 91.84 Billion KRW | 31.79% |
| 2021 | 69.69 Billion KRW | 9.24% |
| 2020 | 63.79 Billion KRW | 22.31% |
| 2019 | 52.15 Billion KRW | 17.73% |
| 2018 | 44.3 Billion KRW | 19.08% |
| 2017 | 37.2 Billion KRW | -8.28% |
| 2016 | 40.56 Billion KRW | 29.44% |
| 2015 | 31.33 Billion KRW | -3.18% |
| 2014 | 32.36 Billion KRW | 34.4% |
| 2013 | 24.08 Billion KRW | 28.52% |
| 2012 | 18.74 Billion KRW | 24.68% |
| 2011 | 15.03 Billion KRW | 14.3% |
| 2010 | 13.15 Billion KRW | -3.7% |
| 2009 | 13.65 Billion KRW | 28.23% |
| 2008 | 10.64 Billion KRW | 36.83% |
| 2007 | 7.78 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 117.97 Billion KRW | 12.28% |
| 2024 Q2 | 118.33 Billion KRW | 0.31% |
| 2023 Q2 | 93.17 Billion KRW | -2.68% |
| 2023 Q4 | 105.07 Billion KRW | 10.77% |
| 2023 FY | 105.07 Billion KRW | 14.41% |
| 2023 Q1 | 95.73 Billion KRW | 4.24% |
| 2023 Q3 | 94.86 Billion KRW | 1.82% |
| 2022 Q1 | 74.35 Billion KRW | 6.69% |
| 2022 FY | 91.84 Billion KRW | 31.79% |
| 2022 Q4 | 91.84 Billion KRW | 10.75% |
| 2022 Q3 | 82.93 Billion KRW | -1.24% |
| 2022 Q2 | 83.97 Billion KRW | 12.94% |
| 2021 FY | 69.69 Billion KRW | 9.24% |
| 2021 Q2 | 71.14 Billion KRW | 8.26% |
| 2021 Q1 | 65.72 Billion KRW | 3.01% |
| 2021 Q3 | 69.66 Billion KRW | -2.08% |
| 2021 Q4 | 69.69 Billion KRW | 0.03% |
| 2020 FY | 63.79 Billion KRW | 22.31% |
| 2020 Q4 | 63.79 Billion KRW | 15.78% |
| 2020 Q2 | 55.4 Billion KRW | -1.14% |
| 2020 Q3 | 55.1 Billion KRW | -0.54% |
| 2020 Q1 | 56.03 Billion KRW | 7.44% |
| 2019 Q3 | 48.73 Billion KRW | 16.76% |
| 2019 Q2 | 41.73 Billion KRW | -4.1% |
| 2019 FY | 52.15 Billion KRW | 17.73% |
| 2019 Q4 | 52.15 Billion KRW | 7.04% |
| 2019 Q1 | 43.52 Billion KRW | -1.77% |
| 2018 Q4 | 44.3 Billion KRW | -3.3% |
| 2018 FY | 44.3 Billion KRW | 19.08% |
| 2018 Q1 | 40.23 Billion KRW | 8.14% |
| 2018 Q2 | 43.37 Billion KRW | 7.81% |
| 2018 Q3 | 45.81 Billion KRW | 5.62% |
| 2017 Q1 | 42.56 Billion KRW | 4.94% |
| 2017 Q4 | 37.2 Billion KRW | -13.3% |
| 2017 FY | 37.2 Billion KRW | -8.28% |
| 2017 Q2 | 41.69 Billion KRW | -2.05% |
| 2017 Q3 | 42.91 Billion KRW | 2.92% |
| 2016 Q2 | 33.9 Billion KRW | 5.01% |
| 2016 FY | 40.56 Billion KRW | 29.44% |
| 2016 Q1 | 32.29 Billion KRW | 3.04% |
| 2016 Q4 | 40.56 Billion KRW | 4.66% |
| 2016 Q3 | 38.75 Billion KRW | 14.3% |
| 2015 FY | 31.33 Billion KRW | -3.18% |
| 2015 Q3 | 30.55 Billion KRW | 1.3% |
| 2015 Q4 | 31.33 Billion KRW | 2.56% |
| 2015 Q2 | 30.16 Billion KRW | -1.31% |
| 2015 Q1 | 30.56 Billion KRW | -5.58% |
| 2014 Q1 | 23.93 Billion KRW | -0.61% |
| 2014 FY | 32.36 Billion KRW | 34.4% |
| 2014 Q4 | 32.36 Billion KRW | -1.07% |
| 2014 Q3 | 32.72 Billion KRW | 18.8% |
| 2014 Q2 | 27.54 Billion KRW | 15.06% |
| 2013 Q3 | 22.32 Billion KRW | 15.47% |
| 2013 Q2 | 19.33 Billion KRW | 3.55% |
| 2013 Q4 | 24.08 Billion KRW | 7.87% |
| 2013 FY | 24.08 Billion KRW | 28.52% |
| 2013 Q1 | 18.67 Billion KRW | -0.35% |
| 2012 Q1 | 17.16 Billion KRW | 0.0% |
| 2012 FY | 18.74 Billion KRW | 24.68% |
| 2012 Q4 | 18.74 Billion KRW | 0.0% |
| 2011 FY | 15.03 Billion KRW | 14.3% |
| 2011 Q2 | 12.99 Billion KRW | -10.96% |
| 2011 Q1 | 14.59 Billion KRW | 10.95% |
| 2011 Q3 | 13.58 Billion KRW | 4.58% |
| 2010 Q3 | 13.31 Billion KRW | 17.0% |
| 2010 Q1 | 13.11 Billion KRW | -3.93% |
| 2010 FY | 13.15 Billion KRW | -3.7% |
| 2010 Q4 | 13.15 Billion KRW | -1.24% |
| 2010 Q2 | 11.38 Billion KRW | -13.26% |
| 2009 Q3 | 11.86 Billion KRW | 4.91% |
| 2009 FY | 13.65 Billion KRW | 28.23% |
| 2009 Q4 | 13.65 Billion KRW | 15.1% |
| 2009 Q1 | 10.89 Billion KRW | 2.29% |
| 2009 Q2 | 11.3 Billion KRW | 3.81% |
| 2008 Q3 | 13.23 Billion KRW | 2.76% |
| 2008 Q1 | 10.4 Billion KRW | 33.72% |
| 2008 FY | 10.64 Billion KRW | 36.83% |
| 2008 Q2 | 12.87 Billion KRW | 23.75% |
| 2008 Q4 | 10.64 Billion KRW | -19.53% |
| 2007 Q1 | 8.31 Billion KRW | 0.0% |
| 2007 Q4 | 7.78 Billion KRW | 0.42% |
| 2007 FY | 7.78 Billion KRW | 0.0% |
| 2007 Q2 | 7.44 Billion KRW | -10.4% |
| 2007 Q3 | 7.74 Billion KRW | 4.04% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -137.991% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 10.839% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | -15.26% |
| HANDOK Inc. | 94.46 Billion KRW | -11.235% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -394.645% |
| Yuhan Corporation | 284.75 Billion KRW | 63.099% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 9.66% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -546.288% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 63.617% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -224.473% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -70.237% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -439.496% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -247.018% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -117.34% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -137.991% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -236.349% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -198.717% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -118.329% |
| JW Holdings Corporation | 147.58 Billion KRW | 28.804% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | -24.171% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 59.807% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 0.955% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -94.866% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -289.207% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -223.203% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 4.273% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -137.991% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 44.298% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 56.498% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 0.955% |
| Yuhan Corporation | 284.75 Billion KRW | 63.099% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 16.126% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -69.517% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 59.561% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 0.955% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | -32.003% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -113.825% |
| CKD Bio Corp. | 69.08 Billion KRW | -52.106% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | -48.631% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -94.38% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -94.866% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 46.049% |
| Boryung Corporation | 189.8 Billion KRW | 44.639% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -84.893% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -70.237% |
| JW Lifescience Corporation | 23.39 Billion KRW | -349.078% |